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Background: Over the past few years, data have 
been published concerning the relative efficacy 
and safety profiles of tamoxifen and the aromatase 
inhibitors (AIs) in the adjuvant therapy setting for 
women with early hormone receptor-positive breast 
cancer. Recently, debate has centred around trials 
which have studied primary tamoxifen and AI 
therapy, switching and sequencing strategies and 
extended adjuvant therapy.
Methods: Here, a group of 24 breast cancer 
experts review efficacy and safety data from 
the recent major trials investigating tamoxifen 
and the third-generation AIs in postmenopausal 
women, which have challenged the perception 
of tamoxifen as optimum adjuvant endocrine 
therapy. Data from the Arimidex, Tamoxifen, Alone 
or in Combination (ATAC) trial, Breast International 
Group (BIG) 1-98 study, National Cancer Institute 
of Canada MA 17 trial, Intergroup Exemestane 
Study (IES), Italian Tamoxifen Anastrozole (ITA) trial, 
Austrian Breast and Colorectal Cancer Study Group 
(ABCSG) Trial 8 and Arimidex-Nolvadex (ARNO) 95 
are considered to provide a rational interpretation 
of the impact of these data on current practice, 
and to highlight areas where further investigation 
is needed.
Conclusion: We can be confident that AIs 
represent superior adjuvant endocrine treatment 
to tamoxifen in postmenopausal women, either 
as initial therapy or as an alternative for women 
who have started adjuvant therapy with tamoxifen. 
However, there remain issues regarding the best 
way to use AIs, such as the optimal length of 
AI treatment and how a sequence of tamoxifen 
followed by an AI compares with AI monotherapy; 
these will require further data to resolve.
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Introduction
In	 recent	 years,	 a	 large	 body	 of	 data	 relating	 to	








careful	 interpretation	 to	 determine	 the	 extent	 of	
benefit	with	each	therapy,	especially	where	different	
treatment	 strategies	 are	 employed.	 In	 particular,	
data	 from	the	 ‘Arimidex’,	Tamoxifen,	Alone	or	 in	
Combination	(ATAC)	trial1,	the	Breast	International	




















































the	 prevention	 of	 recurrence	 appears	 to	 be	 of	
paramount	importance.	The	contrasting	safety	profiles	


































































































for	women	with	 hormone	 receptor-positive	 early	
breast	cancer,	and	should	therefore	be	offered	to	newly	
diagnosed	patients	as	their	initial	treatment.
It	 is	 important	 to	distinguish	between	 switching	
strategy	trials	(where	patients	who	have	completed	















Figure 1. Kaplan-Meier curves showing (A) time to recurrence in the ATAC trial (hormone receptor-positive patients) 
(reproduced with permission from reference 1), and (B) disease-free survival in BIG 1-98 (all patients)(reproduced with 



























HR 0.74; 95% CI 0.64–0.87
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Trial	8	 and	ARNO	955,	 indicate	 that	 switching	 to	
an	AI	from	tamoxifen	after	2–3	years	of	 treatment	








32%	 in	 IES	with	 exemestane	 (HR	=	0.68;	95%	CI	
0.56–0.82;	p <	0.001).	Consequently,	AIs	appear	to	be	
the	treatment	of	choice	not	only	for	newly	diagnosed	











comparing	 5	years	 of	 letrozole	with	 tamoxifen-to-
letrozole	(and	vice versa)	sequenced	treatment	strategies,	











































Table 1. Efficacy data from primary adjuvant, switched adjuvant and extended adjuvant trials, comparing adjuvant 
strategies involving aromatase inhibitors with 5 years of adjuvant tamoxifen
Trial	 AI	 Follow-up,	months	 Outcome	measure*	 HR	vs.	5	years’	T	 95%	CI,	p-value	
Primary	adjuvant	therapy	trials	
	 ATAC	 A	 68	 DFS	 0.87	 0.78–0.97,	0.01	
	 BIG	1-98	 L	 26	 DFS	 0.81	 0.70–0.93,	0.003	
Switching	trials	
	 IES	 E	 31	 DFS	 0.68	 0.56–0.82,	<	0.001	
	 ABCSG	8/ARNO	95	 A	 28	 EFS	 0.60	 0.44–0.81,	0.0009	
	 ITA	 A	 36	 DFS	 0.35	 0.18–0.68,	0.001	
Extended	adjuvant	therapy	trials 
	 MA	17	 L	 30	 DFS	 0.58	 0.45–0.76,	<	0.001	
	 ABCSG	6a	 A	 60	 EFS	 0.64	 0.41–0.99,	0.047	
*Outcome	measures	may	be	defined	differently	for	different	trials	





























































































micrometastases	 have	 altered	 receptor	 expression	
but	whose	disease	has	not	yet	recurred,	while	those	
continuing	on	tamoxifen	are	more	likely	to	experience	




























exploratory	 analyses)	 be	 confirmed,	 uncertainties	






are	 bound	 by	 the	 assumptions	 on	which	 they	 are	
constructed,	and	necessitate	improvement	as	new	data	
are	published,	it	appears	that	the	effect	of	the	excess	
Figure 2. Kaplan-Meier estimates for incidence of recurrence with different adjuvant treatment strategies in the ‘Deep’ model 
(reproduced with permission from reference 18)
5 years of tamoxifen
5 years of aromatase inhibitor
3 years of aromatase inhibitor after 2 years of tamoxifen















































































































from	 adjuvant	 endocrine	 trials	 has	 brought	 about	
speculation	as	to	the	efficacy	of	AI	therapy	in	certain	
patient	populations.	 For	 example,	 in	ATAC	 there	











































the	 first	 2.5	 years	 of	 the	 5-year	 adjuvant	 therapy	







of	median	 follow-up	 [	p <	0.001],	 respectively)1,2.	
Where	an	AI	is	given	after	tamoxifen,	the	incidence	of	
vaginal	bleeding	is	also	lower	in	the	AI-treated	group	
(5.5%	 and	 4.0%	 for	 tamoxifen	 and	 exemestane,	
respectively,	in	IES	at	31	months	of	median	follow-up	
[	p =	0.05])4.
An	 unavoidable	 consequence	 of	 an	 increase	 in	
gynaecological	 adverse	 events	 is	 an	 increase	 in	
gynaecological	investigations	to	rule	out	malignancy.	

































































of	 treatment,	 the	 consequences	 of	 gynaecological	
adverse	events	may	be	considerably	greater	than	the	
physiological	event	itself.	Furthermore,	the	occurrence	
of	 gynaecological	 adverse	 events	may	 lead	 to	 an	
increased	rate	of	prophylactic	hysterectomy.	In	ATAC,	
there	were	almost	four	times	as	many	hysterectomies	

























5	years’	 tamoxifen,	 patients	 receiving	 letrozole	








patients	and	a	control	population,	 it	 is	difficult	 to	
estimate	 the	extent	 to	which	AI	 therapy	 increases	
fracture	risk	over	 that	which	could	be	expected	 in	


































receiving	 tamoxifen	alone	 in	 IES	 (5.4%	and	3.6%,	
respectively,	at	31	months	of	follow-up),	also	shows	





is	 currently	 being	 assessed	 in	 the	Zometa/Femara	
Adjuvant	 Synergy	 Trial	 (Z-FAST)33.	 Preliminary	
findings	at	6	months	show	that	 the	total	hip	BMD	
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The	mechanisms	by	which	AIs	increase	the	incidence	










serious	 adverse	 events	 associated	with	 tamoxifen,	
namely	DVT,	stroke	and	endometrial	cancer.	In	the	
ATAC	study,	at	a	median	follow-up	of	68	months,	


























of	 tamoxifen	 and	AIs	 on	 lipid	profiles	 and	 risk	of	
CHD	 is	 unclear.	 The	Women’s	Health	 Initiative	







ifen	has	 a	 cardioprotective	 effect	 as	 a	 result	of	 its	
significant	lowering	of	total	(	p	<	0.01)	and	low-density	








































































































































events	 for	 letrozole	compared	with	 tamoxifen	was	

















cardiac	 risk	 with	 AIs	 compared	 with	 tamoxifen	
would	 have	 been	 detected	 in	 the	 current	 pool	 of	
data.	Therefore,	current	evidence	suggests	that	CHD	















tamoxifen	 for	 breast	 cancer	 is	 also	 associated	
with	 a	 significantly	 increased	 risk	 of	 developing	
a	major	venous	 thromboembolic	event	 (odds	 ratio	
2.1;	95%	CI,	1.1–4.1)45.	The	impact	of	the	increased	
risk	of	a	venous	 thromboembolic	event	 in	patients	






Data	 from	 ATAC	 at	 68	 months	 of	 follow-up	
show	a	significant	decrease	in	the	incidence	of	stroke	























Current	 data	 confirm	 the	 superiority	 of	AIs	 over	











































































Serious	 gynaecological	 adverse	 events	 are	more	
common	with	tamoxifen	therapy	than	AI	treatment.	
Such	 events	 not	 only	 lead	 to	 inconvenience	 and	
follow-up	treatment	for	the	patient,	but	also	increase	
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